Schizophrenia News

ATLANTA — Lisa Dixon, MD, MPH, of New York-Presbyterian and Columbia University Medical Center, discusses the benefits of coordinated specialty care for early-onset schizophrenia and how to overcome systemic and organizational challenges of implementation.

The FDA recently announced that olanzapine, an antipsychotic for treatment of schizophrenia and bipolar disorder, can cause eosinophilia with systemic symptoms.

Recent study data showed that men with schizophrenia or bipolar disorder were more likely to have a history of Candida albicans yeast infections than men without the disorders. Moreover, women with schizophrenia or bipolar disorder who tested positive for C. albicans were more likely to have delayed memory than women with the disorders but no history of infection.

The FDA recently reported that most of the issues identified with the Clozapine Risk Evaluation and Mitigation Strategy program have been resolved.

The FDA has added new warnings to aripiprazole drug labels regarding compulsive or uncontrollable urges to gamble, binge eat, shop and have sex associated with use of the antipsychotic.

The FDA recently approved Nuplazid for hallucinations and delusions among individuals with Parkinson’s disease.

BALTIMORE — Mental health diagnoses and care significantly increased among military-connected children within the last 15 years, according to data presented at the Pediatric Academic Societies Meeting.

The FDA has issued a complete response letter for Digital Medicine, a drug/device combination product from Otsuka Pharmaceutical Inc. and Proteus Digital Health that combines an atypical antipsychotic and an ingestible sensor.

Physical and mental exercise may restore neural connections affected by schizophrenia in young adults and improve cognitive function, according to recent findings.

Recent findings suggest that brain abnormalities associated with psychosis are present at a young age before clinical high-risk symptoms are typically identified.